Mohammad Rahbari

Medical Doctor | Clinician Scientist @DKFZ @CancerInflam @UniHeidelberg Interested in #microbiome, #inflammation and #cancer

[Human Cell Atlas @humancellatlas]

Remember that Day 3 of the 2026 HCA General Meeting (18 June) will be held at the Broad Institute. Discussions this day will inform and influence the next phase of HCA. Please join us to shape the future!
#HCA2026GM https://t.co/XlUvVdFwPw

[EASL Education @EASLedu]

Missed #EASLStudio at #EASLCongress 2026? 🎙️

Catch up on all 10 episodes, from MASH cirrhosis and HBV cure strategies to PBC care, landmark studies, liver policy, and the future of hepatology.

▶️ https://t.co/Oc6siWKIQP

Discover them below 👇

[Nuh Rahbari @NuhNRahbari]

𝐑𝐨𝐛𝐨𝐭𝐢𝐜 𝐯𝐬. 𝐋𝐚𝐩𝐚𝐫𝐨𝐬𝐜𝐨𝐩𝐢𝐜 𝐇𝐞𝐩𝐚𝐭𝐞𝐜𝐭𝐨𝐦𝐲: 𝐖𝐡𝐲 𝐓𝐞𝐱𝐭𝐛𝐨𝐨𝐤 𝐎𝐮𝐭𝐜𝐨𝐦𝐞 𝐦𝐚𝐭𝐭𝐞𝐫𝐬
🤖 Higher likelihood of achieving TO
📉 Failure to achieve TO impaired patient-rep QoL and functional recovery @HepatobiliaryN
👉 https://t.co/TLqt6VXG3j

[Nature Reviews Cancer @NatureRevCancer]

Our JUNE issue is now live!☀️🍉

It features #REVIEWs on:
- Balancing type I interferon signalling
- Interplay between steatotic liver disease and liver cancer
- KMT2C/KMT2D-COMPASS complex loss in cancer
- #ExpertRecommendation on ovarian cancer
📖👇
https://t.co/HlOyH3ml0E

[Annals of Oncology @Annals_Oncology]

📢 #ASCO26 Concomitant publication: Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trial
https://t.co/zW9yRwAhnD

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Nuh Rahbari @NuhNRahbari]

𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐇𝐨𝐦𝐞: 𝐏𝐫𝐨𝐟. 𝐌𝐚𝐫𝐤𝐮𝐬 𝐖. 𝐁ü𝐜𝐡𝐥𝐞𝐫
𝐏𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐜 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 𝐌𝐚𝐬𝐭𝐞𝐫𝐜𝐥𝐚𝐬𝐬 𝐢𝐧 𝐔𝐥𝐦 𝐨𝐧 𝐉𝐮𝐥𝐲 𝟐𝟑, 𝟐𝟎𝟐𝟔
📝Slots are limited. Please sign up via the registration link: https://t.co/GqzoPtFMAn
See you in Ulm 👍

[Mohammad Rahbari @MoRahbari]

@BavenoCoop @EASLedu @ValdigGroup @VirginiaHdezGea @jcgarciapagan @EASLnews @APASLnews @alehlatam @AASLDtweets @AisfFegato @AEEHLiver @ReibergerThomas Important work for this understudies field!

[Mohammad Rahbari @MoRahbari]

Proud of the new work by my colleagues @GallageSuchira and @CancerInflam:

https://t.co/STBgtnm29o

An important guideline on how to use preclinical models to study the pathobiogy of fatty liver disease.

@EASLnews @DKFZ @EASLedu @JHepatology

[Mohammad Rahbari @MoRahbari]

@Valeriechew29 Intriguing indeed!

[Mathias Heikenwälder @CancerInflam]

The "EASL position paper on preclinical models of steatotic liver disease" is out - a great team effort.
https://t.co/LAmAZioOmD

[Mathias Heikenwälder @CancerInflam]

Thank you to Suchira Gallage, Rui Castro, Jennifer Estall, Ira Tabas, Quentin Anstee, Dina Tiniakos Gyongyi Szabo, Jun Yu, Chantal Desdouets, Frank Tacke and, Fiona Oakley - it was more than a pleasure to work on this with you - @EASLnews @EASLedu @JHepatology

[Mohammad Rahbari @MoRahbari]

@CancerInflam @EASLnews @EASLedu @JHepatology Excellent resource and an important guideline for the field!

[OncoDaily GI @OncoDailyGI]

🔟 Must-Read in GI Oncology | 3rd week of April

A week of key updates across GI cancers, from real-world data to emerging biology and evolving clinical strategies.

• G9a inhibition → improved IO response in HCC
• STRIDE (durva+tremi) shows real-world effectiveness in HCC
• RASolute302: promising momentum in pancreatic cancer
• Young-onset upper GI cancers → need for dedicated programmes
• CAVE-GOIM: supports anti-EGFR rechallenge in mCRC
• Early-onset CRC (AACR): distinct biology in 30–39 pts
• High-volume centers → better outcomes in upper GI surgery
• AGEO analysis: antiangiogenics active in SBA
• New ESMO guidelines for metastatic CRC
• MASLD/ALD →metabolic and immune drivers of liver cancer

💡 Takeaway: Precision is accelerating in GI oncology—driven by biology, real-world evidence, and better patient stratification.

@casadei_gardini @JessieAElliott @DCiardiello @ArndtVogel @MoRahbari

📎 https://t.co/m2mxRxrm2H

#GIONC #Oncology #CRC #HCC #PancreaticCancer #RASolute302 #gastricCancer

[DKFZ @DKFZ]

Researchers from DKFZ, University Hospital Tübingen & Sanford Burnham Prebys Medical Discovery Institute discovered that chronic cellular stress promotes liver cancer - but at the same time renders tumors vulnerable to immunotherapy. @Nature @CancerInflam
https://t.co/nSWbnYrw7z

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models https://t.co/ct6S5PDAQu

[Nuh Rahbari @NuhNRahbari]

🤖📹Happy to share our video paper and introduce 𝐂𝐑𝐔𝐒𝐇 (𝐂ontinuous 𝐑obotic 𝐔ltra𝐒ound ���epatectomy): a novel technique designed specifically for robotic parenchyma-sparing liver surgery
👉 Video can be accessed @AnnSurgOncol: https://t.co/TMVXNekubS
#roboticliversurgery

[Ankur Sharma @asharmaiisc]

Towards a reference cell atlas of liver diversity over the human lifespan

Human Liver Cell Atlas (HLiCA) roadmap paper is out in @NatRevGastroHep

Led by Sarah Taylor, @garybader1 @MacparlandSonya & Alan Mullar

https://t.co/hJkO3YGzj8

[Human Cell Atlas @humancellatlas]

Wonderful to see this Roadmap ‘Towards a reference cell atlas of liver diversity over the human lifespan’ in @NatRevGastroHep. It reveals how the HCA Liver Biological Network is creating the Human Liver Cell Atlas, including challenges and potential impact on disease research.